U.S. markets open in 7 hours 46 minutes
  • S&P Futures

    3,930.25
    +7.75 (+0.20%)
     
  • Dow Futures

    32,002.00
    +86.00 (+0.27%)
     
  • Nasdaq Futures

    13,329.25
    +27.25 (+0.20%)
     
  • Russell 2000 Futures

    2,299.10
    +14.00 (+0.61%)
     
  • Crude Oil

    63.41
    +0.19 (+0.30%)
     
  • Gold

    1,793.40
    -4.50 (-0.25%)
     
  • Silver

    27.95
    +0.09 (+0.33%)
     
  • EUR/USD

    1.2183
    +0.0015 (+0.12%)
     
  • 10-Yr Bond

    1.3890
    0.0000 (0.00%)
     
  • Vix

    21.34
    -1.77 (-7.66%)
     
  • GBP/USD

    1.4157
    +0.0016 (+0.11%)
     
  • USD/JPY

    105.9450
    +0.0630 (+0.06%)
     
  • BTC-USD

    50,427.37
    -4.79 (-0.01%)
     
  • CMC Crypto 200

    1,005.52
    +10.85 (+1.09%)
     
  • FTSE 100

    6,658.97
    +33.03 (+0.50%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, July 13, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced that effective as of market open on July 14, 2020, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol "RLMD."

Relmada Therapeutics Corporate Logo
Relmada Therapeutics Corporate Logo

The Nasdaq Global Select Market® is a mark of achievement and stature for qualified companies. Listed companies must meet financial and liquidity requirements and satisfy corporate governance and disclosure requirements on both an initial and continuing basis.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, REL-1017 (dextromethadone) is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.

Investor Contact:

Tim McCarthy
LifeSci Advisors
212-915-2564
tim@lifesciadvisors.com

For Media Inquiries:

FischTank PR
relmada@fischtankpr.com

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/relmada-therapeutics-announces-uplisting-to-the-nasdaq-global-select-market-301092149.html

SOURCE Relmada Therapeutics, Inc.